Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Open in Screener

SPRY

ARS Pharmaceuticals Inc

Jan 17 • 04:00PM ET

12.57

Dollar change +0.39
Percentage change 3.20	%

Healthcare • Biotechnology • USA • NASD

Peers: ALNY IONS RNA ARWR SRPT NBIX ENTA VRTX RARE ASND

| Held by: VTI XBI IWM VXF IWO IBB SCHA VTWO LABU IWC

Index	RUT	P/E	-	EPS (ttm)	-0.51	Insider Own	47.40%	Shs Outstand	97.15M	Perf Week	11.83%
Market Cap	1.22B	Forward P/E	-	EPS next Y	-0.36	Insider Trans	-10.88%	Shs Float	51.12M	Perf Month	5.76%
Income	-49.10M	PEG	-	EPS next Q	-0.13	Inst Own	42.21%	Short Float	26.75%	Perf Quarter	-23.91%
Sales	2.57M	P/S	475.34	EPS this Y	2.19%	Inst Trans	2.51%	Short Ratio	11.08	Perf Half Y	20.34%
Book/sh	2.07	P/B	6.08	EPS next Y	35.43%	ROA	-21.07%	Short Interest	13.68M	Perf Year	106.40%
Cash/sh	2.11	P/C	5.97	EPS next 5Y	-	ROE	-22.41%	52W Range	5.81 - 18.51	Perf YTD	19.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-1.44%	ROI	-24.43%	52W High	-32.09%	Beta	0.95
Dividend TTM	-	Quick Ratio	12.50	Sales past 5Y	-43.45%	Gross Margin	93.22%	52W Low	116.52%	ATR (14)	0.85
Dividend Ex-Date	-	Current Ratio	12.54	EPS Y/Y TTM	79.10%	Oper. Margin	-2356.15%	RSI (14)	58.87	Volatility	9.30% 7.28%
Employees	26	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-1912.15%	Recom	1.00	Target Price	30.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-26.75%	Payout	-	Rel Volume	1.36	Prev Close	12.18
Sales Surprise	259.65%	EPS Surprise	-40.35%	Sales Q/Q	-	Earnings	Nov 13 BMO	Avg Volume	1.23M	Price	12.57
SMA20	11.46%	SMA50	-2.98%	SMA200	8.16%	Trades		Volume	1,679,780	Change	3.20%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-24	Initiated	Cantor Fitzgerald	Overweight
Aug-13-24	Upgrade	Raymond James	Outperform → Strong Buy	$18 → $22
Aug-12-24	Reiterated	Leerink Partners	Outperform	$19 → $20
Jul-25-24	Initiated	Raymond James	Outperform	$18
Mar-05-24	Upgrade	Leerink Partners	Market Perform → Outperform	$6 → $18
Feb-20-24	Upgrade	William Blair	Mkt Perform → Outperform
Sep-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Jan-31-23	Initiated	Wedbush	Outperform	$10
Jan-03-23	Initiated	William Blair	Outperform	$17
Dec-13-22	Initiated	SVB Leerink	Outperform	$14

Jan-13-25 04:15PM	BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. (Investor's Business Daily)
08:00AM	ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy (epinephrine nasal spray) (GlobeNewswire)
Jan-07-25 08:15AM	ARS Pharmaceuticals files for approval of neffy in Canada, U.K. (TipRanks)
06:43AM	ARS Pharma seeks approval for epinephrine spray in Canada and UK (Medical Device Network)
Jan-06-25 08:00AM	ARS Pharmaceuticals Files for Approval of neffy in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abell A/S (GlobeNewswire)
08:00AM	Loading…
08:00AM	ARS Pharmaceuticals Files for Approval of neffy in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abello A/S (GlobeNewswire)
Dec-19-24 05:25PM	ARS Pharmaceuticals Announces neffy (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies (GlobeNewswire)
Dec-18-24 08:00AM	ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.80%
Dec-12-24 02:32PM	ARS Pharmaceuticals Announces Filings for Approval of neffy in China, Japan and Australia (GlobeNewswire)
Dec-04-24 08:00AM	ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost (GlobeNewswire) +5.95%
Nov-14-24 02:08AM	ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ... (GuruFocus.com)
Nov-13-24 07:40AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -15.23%
06:30AM	ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-12-24 07:06AM	ARS Pharmaceuticals announces agreement with ALK to commercialize neffy (TipRanks) -5.03%
Nov-11-24 04:02PM	ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray (Investor's Business Daily)
11:01AM	Loading…
11:01AM	ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m (Pharmaceutical Technology)
07:41AM	ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 (Benzinga)
07:00AM	ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy in Europe, Canada and Other Geographies Outside the United States (GlobeNewswire)
Nov-09-24 05:30PM	ALK licenses rights to neffy , the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) (GlobeNewswire)
Nov-06-24 09:55AM	Wall Street Analysts Think ARS Pharmaceuticals, Inc. (SPRY) Could Surge 67.56%: Read This Before Placing a Bet (Zacks)
08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences (GlobeNewswire)
Oct-24-24 08:30AM	ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
Oct-14-24 09:55AM	Wall Street Analysts Believe ARS Pharmaceuticals, Inc. (SPRY) Could Rally 76.79%: Here's is How to Trade (Zacks)
Sep-30-24 10:33AM	Neffy nasal spray: a game changer for asthma patients and epinephrine delivery? (Pharmaceutical Technology)
Sep-23-24 08:00AM	ARS Pharmaceuticals Announces U.S. Availability of neffy (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis (GlobeNewswire)
Sep-11-24 08:20AM	ARS Pharmaceuticals (SPRY): A Bull Case Theory (Insider Monkey)
Sep-10-24 04:05PM	ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-09-24 04:47PM	ARS Pharmaceuticals Submits sNDA to FDA for neffy 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.) (GlobeNewswire)
Sep-06-24 12:00PM	ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why (Zacks)
Sep-04-24 08:00AM	ARS Pharmaceuticals Launches Pre-Ordering Services for neffy to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis (GlobeNewswire)
10:08AM	Loading…
Aug-27-24 10:08AM	Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned (UPDATED) (Benzinga) +5.76%
Aug-26-24 09:29AM	EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Aug-22-24 12:27AM	ARS Pharmaceuticals Inc (SPRY) CFO Kathleen Scott Sells 12,500 Shares (GuruFocus.com)
Aug-20-24 12:21PM	ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst (Benzinga)
Aug-15-24 07:02PM	Insider Sale: COO Brian Dorsey Sells 30,000 Shares of ARS Pharmaceuticals Inc (SPRY) (GuruFocus.com)
Aug-12-24 04:32AM	ARS Pharmaceuticals anaphylaxis nasal spray gains FDA approval (Pharmaceutical Technology)
Aug-09-24 01:34PM	FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment (Benzinga) +10.01%
12:49PM	ARS Pharmaceuticals Receives FDA Approval of neffy (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis (GlobeNewswire)
Aug-07-24 09:01AM	ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Aug-06-24 05:20PM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:01PM	ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 10:01AM	ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jun-28-24 06:30AM	ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire) +5.71%
May-12-24 09:01PM	ARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Regulatory ... (GuruFocus.com)
May-09-24 11:54PM	SPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024 (InvestorPlace)
04:05PM	ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-30-24 09:01AM	ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand (GlobeNewswire)
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-03-24 09:01AM	ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) (GlobeNewswire)
Apr-01-24 12:00PM	ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know (Zacks) -7.34%
Mar-26-24 08:50AM	Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why (Zacks) +9.53%
Mar-21-24 10:53PM	SPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
05:33PM	ARS Pharmaceuticals Inc (SPRY) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
04:05PM	ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-15-24 06:00AM	Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024 (InvestorPlace)
Mar-07-24 04:05PM	ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy Investor Day (GlobeNewswire)
Mar-06-24 09:01AM	ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Feb-26-24 09:01AM	ARS Pharmaceuticals announces neffy meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study (GlobeNewswire)
Feb-22-24 09:01AM	ARS Pharmaceuticals to Host Virtual neffy Investor Day on March 7, 2024 (GlobeNewswire)
Feb-20-24 09:01AM	ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA's Complete Response Letter (GlobeNewswire)
Feb-05-24 09:01AM	ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy (epinephrine nasal spray) at 2024 AAAAI Annual Meeting (GlobeNewswire)
Nov-09-23 04:00PM	ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) +8.75%
11:02AM	ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis (GlobeNewswire)
Oct-06-23 09:03AM	ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy (epinephrine nasal spray) (GlobeNewswire) +7.02%
Oct-03-23 09:03AM	Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology (GlobeNewswire)
03:01AM	Chief Legal Officer Alexander Fitzpatrick Buys 86,258 Shares of ARS Pharmaceuticals Inc (GuruFocus.com)
Sep-29-23 07:50PM	ARS Pharmaceuticals, Harmonic, and More Stocks See Action From Activist Investors (Barrons.com)
01:39PM	Hedge Fund and Insider Trading News: Dan Loeb, Crispin Odey, Ray Dalio, D. E. Shaw, Eisler Capital, Glazer Capital, Gatos Silver Inc (GATO), ARS Pharmaceuticals Inc (SPRY), and More (Insider Monkey)
10:00AM	Small Biotech Stocks Haven't Shined of Late, but I Think These 3 Could Be Stars (TheStreet.com)
10:00AM	3 Small Biotech Stocks That Could Be Stars (TheStreet.com)
Sep-21-23 12:28PM	ARS Pharmaceuticals (SPRY) Down on CRL for Nasal Spray (Zacks) +25.68%
10:43AM	Biotech Stock Roundup: GSK's Drug Approval, MRNA's Vaccine News, PTCT & SPRY Down (Zacks)
06:28AM	Feds Message Is Louder Than Its Rate Call. Why Thats Critical for Investors. (Barrons.com)
Sep-20-23 12:42PM	Why Shares of ARS Pharmaceuticals Are Plummeting on Wednesday (Motley Fool) -55.79%
10:31AM	FDA says it needs more research before deciding to approve nasal spray to treat dangerous allergies (AP Finance)
10:26AM	FDAs Surprise Rejection of No-Shot Alternative to EpiPen Halves Shares of ARS Pharma (Barrons.com)
09:49AM	FDA Declines to Approve Epinephrine Nasal Spray, Asks for Additional Data (The Wall Street Journal)
06:13AM	ARS Pharma shares plummet after FDA asks for extra test of nasal spray (Investing.com)
Sep-19-23 10:49PM	FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study (GlobeNewswire) -11.22%
Sep-08-23 07:10PM	Imperial Petroleum, ARS Pharmaceuticals Stock, and More See Action From Activist Investors (Barrons.com)
Aug-10-23 04:00PM	ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jun-20-23 08:00AM	ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis (GlobeNewswire)
May-15-23 02:11PM	ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray (Zacks)
09:00AM	ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-12-23 11:51AM	Why ARS Pharmaceuticals Stock Is Soaring Today (Benzinga) +77.88%
May-11-23 07:01PM	FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis (GlobeNewswire)
May-09-23 09:10AM	ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis (GlobeNewswire) -14.31%
Apr-21-23 10:05AM	Companies Like ARS Pharmaceuticals (NASDAQ:SPRY) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-28-23 09:39AM	ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis (GlobeNewswire)
Mar-25-23 09:10AM	ARS Pharmaceuticals Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-23-23 04:01PM	ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-22-23 06:19AM	One ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider upped their stake in the previous year (Simply Wall St.) -5.56%
Feb-23-23 04:01PM	ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors (GlobeNewswire)
Feb-22-23 04:05PM	ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis (GlobeNewswire)
Feb-09-23 06:30AM	ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023 (GlobeNewswire) +5.76%
05:43AM	Insiders own 34% of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) shares but individual investors control 36% of the company (Simply Wall St.)
Nov-10-22 08:00AM	ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis (GlobeNewswire)

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shawver Laura	Director	Jan 06 '25	Option Exercise	3.15	50,000	157,500	260,346	Jan 07 06:24 PM
Shawver Laura	Director	Jan 06 '25	Sale	11.10	50,000	555,065	210,346	Jan 07 06:24 PM
Shawver Laura	Director	Jan 06 '25	Proposed Sale	11.10	50,000	555,065		Jan 06 04:36 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 17 '24	Sale	11.67	100,000	1,167,100	1,098,499	Dec 19 04:20 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 17 '24	Sale	11.67	100,000	1,167,100	1,098,499	Dec 19 04:20 PM
Chakma Justin	Chief Business Officer	Dec 12 '24	Option Exercise	0.84	117,333	98,560	253,713	Dec 13 07:53 PM
Chakma Justin	Chief Business Officer	Dec 13 '24	Option Exercise	1.44	27,272	39,272	163,652	Dec 13 07:53 PM
Chakma Justin	Chief Business Officer	Dec 12 '24	Sale	12.27	117,333	1,439,124	136,380	Dec 13 07:53 PM
Chakma Justin	Chief Business Officer	Dec 13 '24	Sale	12.06	27,272	328,968	136,380	Dec 13 07:53 PM
Dorsey Brian	Chief Operating Officer	Dec 12 '24	Option Exercise	0.64	25,000	16,000	31,024	Dec 13 07:52 PM
Dorsey Brian	Chief Operating Officer	Dec 11 '24	Option Exercise	0.64	15,000	9,600	21,024	Dec 13 07:52 PM
Dorsey Brian	Chief Operating Officer	Dec 12 '24	Sale	12.30	25,000	307,432	6,024	Dec 13 07:52 PM
Dorsey Brian	Chief Operating Officer	Dec 11 '24	Sale	12.43	15,000	186,426	6,024	Dec 13 07:52 PM
Chakma Justin	Officer	Dec 13 '24	Proposed Sale	12.06	27,272	328,967		Dec 13 05:24 PM
Chakma Justin	Chief Business Officer	Dec 10 '24	Option Exercise	0.84	50,000	42,000	186,380	Dec 12 05:41 PM
Chakma Justin	Chief Business Officer	Dec 10 '24	Sale	13.15	50,000	657,625	136,380	Dec 12 05:41 PM
Chakma Justin	Officer	Dec 10 '24	Proposed Sale	11.50	117,333	1,349,330		Dec 12 05:02 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 10 '24	Sale	13.16	100,000	1,316,420	1,148,499	Dec 11 06:30 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 10 '24	Sale	13.16	100,000	1,316,420	1,148,499	Dec 11 06:30 PM
Dorsey Brian	Officer	Dec 11 '24	Proposed Sale	13.31	61,200	814,572		Dec 11 05:31 PM
Chakma Justin	Director	Dec 10 '24	Proposed Sale	14.02	50,000	701,000		Dec 10 04:48 PM
Lowenthal Richard E	Officer	Dec 10 '24	Proposed Sale	13.40	300,000	4,020,000		Dec 10 11:15 AM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 06 '24	Option Exercise	4.67	25,665	119,852	3,433,512	Dec 09 05:43 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 06 '24	Option Exercise	8.42	11,876	99,996	4,327,189	Dec 09 05:43 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 06 '24	Option Exercise	4.67	25,665	119,852	3,433,512	Dec 09 05:25 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 06 '24	Option Exercise	8.42	11,876	99,996	4,327,189	Dec 09 05:25 PM
Chakma Justin	Chief Business Officer	Dec 06 '24	Option Exercise	0.84	50,000	42,000	186,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 05 '24	Option Exercise	0.84	49,640	41,698	186,020	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 04 '24	Option Exercise	0.84	45,000	37,800	181,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 06 '24	Sale	14.23	50,000	711,615	136,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 05 '24	Sale	14.13	49,640	701,642	136,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 04 '24	Sale	13.95	45,000	627,944	136,380	Dec 06 07:15 PM
Chakma Justin	Officer	Dec 06 '24	Proposed Sale	14.00	50,000	700,000		Dec 06 05:30 PM
Chakma Justin	Officer	Dec 05 '24	Proposed Sale	13.32	49,640	661,205		Dec 05 05:06 PM
Chakma Justin	Chief Business Officer	Dec 02 '24	Option Exercise	0.84	45,000	37,800	181,380	Dec 04 09:45 PM
Chakma Justin	Chief Business Officer	Dec 03 '24	Option Exercise	0.84	45,000	37,800	181,380	Dec 04 09:45 PM
Chakma Justin	Chief Business Officer	Dec 02 '24	Sale	13.67	45,000	615,218	136,380	Dec 04 09:45 PM
Chakma Justin	Chief Business Officer	Dec 03 '24	Sale	13.19	45,000	593,402	136,380	Dec 04 09:45 PM
Shawver Laura	Director	Dec 03 '24	Option Exercise	2.60	87,984	229,010	298,330	Dec 04 09:40 PM
Shawver Laura	Director	Dec 02 '24	Option Exercise	1.27	97,244	123,500	307,590	Dec 04 09:40 PM
Shawver Laura	Director	Dec 04 '24	Option Exercise	3.15	14,772	46,532	225,118	Dec 04 09:40 PM
Shawver Laura	Director	Dec 02 '24	Sale	13.56	97,244	1,318,745	210,346	Dec 04 09:40 PM
Shawver Laura	Director	Dec 03 '24	Sale	13.26	87,984	1,166,897	210,346	Dec 04 09:40 PM
Shawver Laura	Director	Dec 04 '24	Sale	13.75	14,772	203,109	210,346	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 04 '24	Option Exercise	1.50	6,283	9,424	11,976	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 02 '24	Option Exercise	1.50	3,717	5,576	9,410	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 04 '24	Sale	14.00	6,283	87,962	5,693	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 02 '24	Sale	14.11	3,717	52,461	5,693	Dec 04 09:40 PM
ERIC KARAS	Officer	Dec 04 '24	Proposed Sale	14.00	6,283	87,962		Dec 04 05:46 PM
Chakma Justin	Officer	Dec 04 '24	Proposed Sale	14.51	45,000	652,950		Dec 04 05:15 PM
Chakma Justin	Officer	Dec 03 '24	Proposed Sale	13.00	45,000	585,000		Dec 03 05:25 PM
Chakma Justin	Officer	Dec 02 '24	Proposed Sale	14.51	45,000	652,950		Dec 02 07:01 PM
Shawver Laura	Director	Dec 02 '24	Proposed Sale	13.56	200,000	2,713,000		Dec 02 06:22 PM
ERIC KARAS	Officer	Dec 02 '24	Proposed Sale	14.11	3,717	52,461		Dec 02 04:42 PM
Chakma Justin	Chief Business Officer	Nov 26 '24	Sale	14.05	42,186	592,570	161,380	Nov 27 04:11 PM
Chakma Justin	Chief Business Officer	Nov 25 '24	Sale	14.00	32,814	459,422	203,566	Nov 27 04:11 PM
Chakma Justin	Chief Business Officer	Nov 27 '24	Sale	14.39	25,000	359,750	136,380	Nov 27 04:11 PM
Lowenthal Richard E	PRESIDENT AND CEO	Nov 19 '24	Sale	13.95	100,000	1,394,960	1,198,499	Nov 21 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Nov 19 '24	Sale	13.95	100,000	1,394,960	1,198,499	Nov 21 04:30 PM
Chakma Justin	Officer	Nov 15 '24	Proposed Sale	17.30	236,380	4,089,374		Nov 15 03:21 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Nov 12 '24	Sale	16.85	100,000	1,684,642	1,248,499	Nov 14 04:30 PM
Lowenthal Richard E	PRESIDENT AND CEO	Nov 12 '24	Sale	16.85	100,000	1,684,642	1,248,499	Nov 14 04:30 PM
Flynn James E	10% Owner	Nov 11 '24	Sale	18.04	528,456	9,534,642	5,274,735	Nov 13 08:16 PM
Flynn James E	10% Owner	Nov 12 '24	Sale	17.49	34,814	609,064	5,257,328	Nov 13 08:16 PM
Scott Kathleen D.	Chief Financial Officer	Oct 16 '24	Option Exercise	1.50	12,500	18,750	17,449	Oct 17 04:30 PM
Scott Kathleen D.	Chief Financial Officer	Oct 16 '24	Sale	16.00	12,500	200,000	4,949	Oct 17 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Oct 15 '24	Sale	14.88	100,000	1,487,595	1,298,499	Oct 17 04:30 PM
Lowenthal Richard E	PRESIDENT AND CEO	Oct 15 '24	Sale	14.88	100,000	1,487,595	1,298,499	Oct 17 04:30 PM
KATHLEEN D SCOTT	Officer	Oct 16 '24	Proposed Sale	16.00	12,500	200,000		Oct 16 04:01 PM
Tanimoto Sarina	Officer	Oct 15 '24	Proposed Sale	14.00	300,000	4,200,000		Oct 15 11:28 AM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Oct 08 '24	Sale	13.83	100,000	1,382,775	1,346,494	Oct 10 04:28 PM
Lowenthal Richard E	PRESIDENT AND CEO	Oct 08 '24	Sale	13.83	100,000	1,382,775	1,346,494	Oct 10 04:27 PM
Karas Eric	Chief Commercial Officer	Sep 18 '24	Option Exercise	1.50	10,000	15,000	15,693	Sep 19 04:30 PM
Karas Eric	Chief Commercial Officer	Sep 18 '24	Sale	14.00	10,000	140,000	5,693	Sep 19 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Sep 17 '24	Sale	12.93	100,000	1,293,205	1,398,499	Sep 19 04:29 PM
Lowenthal Richard E	PRESIDENT AND CEO	Sep 17 '24	Sale	12.93	100,000	1,293,205	1,398,499	Sep 19 04:26 PM
ERIC KARAS	Officer	Sep 18 '24	Proposed Sale	14.00	10,000	140,000		Sep 18 04:06 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Sep 10 '24	Sale	11.50	100,000	1,149,775	1,396,494	Sep 12 04:25 PM
Lowenthal Richard E	PRESIDENT AND CEO	Sep 10 '24	Sale	11.50	100,000	1,149,775	1,396,494	Sep 12 04:24 PM
Lowenthal Richard E	Officer	Sep 10 '24	Proposed Sale	11.36	300,000	3,408,000		Sep 10 10:31 AM
Thompson Peter A.	Director	Aug 26 '24	Sale	13.00	83,695	1,088,035	0	Aug 28 04:30 PM
ORBIMED ADVISORS LLC	Director	Aug 26 '24	Sale	13.00	83,695	1,088,035	0	Aug 28 04:26 PM
Thompson Peter A.	Director	Aug 21 '24	Sale	13.56	407,700	5,526,601	544,677	Aug 23 06:41 PM
Thompson Peter A.	Director	Aug 22 '24	Sale	12.94	391,482	5,065,777	153,195	Aug 23 06:41 PM
Thompson Peter A.	Director	Aug 23 '24	Sale	13.03	69,500	905,585	83,695	Aug 23 06:41 PM
ORBIMED ADVISORS LLC	Director	Aug 21 '24	Sale	13.56	407,700	5,526,601	544,677	Aug 23 06:38 PM
ORBIMED ADVISORS LLC	Director	Aug 22 '24	Sale	12.94	391,482	5,065,777	153,195	Aug 23 06:38 PM
ORBIMED ADVISORS LLC	Director	Aug 23 '24	Sale	13.03	69,500	905,585	83,695	Aug 23 06:38 PM
Dorsey Brian	Chief Operating Officer	Aug 20 '24	Option Exercise	0.64	50,000	32,000	56,024	Aug 21 06:51 PM
Dorsey Brian	Chief Operating Officer	Aug 20 '24	Sale	15.00	50,000	750,000	6,024	Aug 21 06:51 PM
Karas Eric	Chief Commercial Officer	Aug 19 '24	Option Exercise	1.50	10,000	15,000	15,693	Aug 21 06:51 PM
Karas Eric	Chief Commercial Officer	Aug 19 '24	Sale	14.00	10,000	140,000	5,693	Aug 21 06:51 PM
Scott Kathleen D.	Chief Financial Officer	Aug 20 '24	Option Exercise	1.50	12,500	18,750	25,699	Aug 21 06:49 PM
Scott Kathleen D.	Chief Financial Officer	Aug 20 '24	Sale	16.00	12,500	200,000	13,199	Aug 21 06:49 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Aug 20 '24	Sale	15.03	100,000	1,502,587	1,497,447	Aug 21 06:48 PM
Lowenthal Richard E	PRESIDENT AND CEO	Aug 20 '24	Sale	15.03	100,000	1,502,587	1,497,447	Aug 21 06:47 PM
OrbiMed Partners Master Fund L	Shareholder	Aug 21 '24	Proposed Sale	14.89	952,377	14,180,894		Aug 21 06:43 PM
KATHLEEN D SCOTT	Officer	Aug 20 '24	Proposed Sale	16.00	12,500	200,000		Aug 20 04:18 PM
BRIAN T DORSEY	Officer	Aug 20 '24	Proposed Sale	15.00	50,000	750,000		Aug 20 04:05 PM
ERIC KARAS	Officer	Aug 19 '24	Proposed Sale	14.00	10,000	140,000		Aug 19 04:17 PM

Open in Screener

NUVL

Nuvalent Inc

Jan 17 • 04:00PM ET

75.84

Dollar change -0.15
Percentage change -0.20	%

Healthcare • Biotechnology • USA • NASD

Peers: ARQT ABUS TIL ALLO BEAM IMTX KRYS RGNX DTIL

| Held by: VTI VB IWM VBR XBI VXF IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-3.48	Insider Own	39.68%	Shs Outstand	65.50M	Perf Week	-1.01%
Market Cap	5.39B	Forward P/E	-	EPS next Y	-4.51	Insider Trans	-11.17%	Shs Float	42.86M	Perf Month	-13.25%
Income	-224.28M	PEG	-	EPS next Q	-1.08	Inst Own	65.55%	Short Float	13.28%	Perf Quarter	-27.64%
Sales	0.00M	P/S	-	EPS this Y	-80.21%	Inst Trans	3.37%	Short Ratio	12.03	Perf Half Y	-5.00%
Book/sh	15.81	P/B	4.80	EPS next Y	-15.29%	ROA	-27.79%	Short Interest	5.69M	Perf Year	2.74%
Cash/sh	16.44	P/C	4.61	EPS next 5Y	-	ROE	-29.57%	52W Range	61.79 - 113.51	Perf YTD	-3.12%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-72.54%	ROI	-20.01%	52W High	-33.19%	Beta	1.38
Dividend TTM	-	Quick Ratio	23.07	Sales past 5Y	0.00%	Gross Margin	-	52W Low	22.73%	ATR (14)	3.31
Dividend Ex-Date	-	Current Ratio	23.07	EPS Y/Y TTM	-71.14%	Oper. Margin	-	RSI (14)	38.10	Volatility	5.01% 4.07%
Employees	92	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.29	Target Price	115.08
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-117.92%	Payout	-	Rel Volume	1.07	Prev Close	75.99
Sales Surprise	-	EPS Surprise	-37.03%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	472.95K	Price	75.84
SMA20	-4.28%	SMA50	-12.97%	SMA200	-7.87%	Trades		Volume	504,511	Change	-0.20%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-30-24	Initiated	H.C. Wainwright	Buy	$110
Oct-24-24	Initiated	UBS	Neutral	$100
Aug-29-24	Initiated	Barclays	Overweight	$100
Apr-17-24	Initiated	Jefferies	Buy	$97
Apr-01-24	Upgrade	Leerink Partners	Market Perform → Outperform	$69 → $110
Feb-28-24	Resumed	Guggenheim	Buy	$99
Feb-23-24	Initiated	Robert W. Baird	Outperform	$105
Sep-27-23	Initiated	Stifel	Buy	$65
Aug-08-23	Initiated	SVB Securities	Market Perform	$42
Jul-24-23	Initiated	Guggenheim	Buy	$56
Jan-18-23	Initiated	Wedbush	Outperform	$39
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$28

Show Previous Ratings

Jan-13-25 06:30AM	Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones (PR Newswire) -6.20%
Dec-30-24 09:43AM	American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls (The Fly)
Dec-19-24 06:30AM	Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-09-24 06:30AM	Nuvalent Appoints Grant Bogle to Board of Directors (PR Newswire)
Nov-26-24 06:52AM	Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference (PR Newswire)
06:30AM	Loading…
Nov-12-24 06:30AM	Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results (PR Newswire)
Sep-18-24 04:05PM	Nuvalent Announces Closing of Upsized Public Offering of Common Stock (PR Newswire)
Sep-16-24 10:23PM	Nuvalent Announces Pricing of Upsized Public Offering of Common Stock (PR Newswire) +28.27% -6.61%
04:04PM	Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths (Investor's Business Daily)
11:18AM	Cancer Biotech Nuvalents Stock Jumps on Positive Data (Barrons.com)
07:00AM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
Sep-14-24 07:57PM	Nuvalent, Inc. (NUVL): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
05:29PM	Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
05:00AM	Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines (PR Newswire)
Sep-13-24 09:53AM	Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655 (PR Newswire) +7.06%
06:30AM	Loading…
Sep-09-24 06:30AM	Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles (PR Newswire)
Aug-29-24 06:30AM	Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (PR Newswire)
Aug-08-24 06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results (PR Newswire)
Jul-23-24 04:52AM	Nuvalent doses first subject in Phase Ia/Ib trial of lung cancer treatment (Clinical Trials Arena)
Jul-22-24 06:30AM	Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor (PR Newswire)
Jul-16-24 06:30AM	Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024 (PR Newswire)
Jul-11-24 06:30AM	Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer (PR Newswire)
Jun-24-24 06:00AM	3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally (InvestorPlace)
May-29-24 06:30AM	Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference (PR Newswire)
May-17-24 04:48PM	Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing (MT Newswires)
06:31AM	FDA grants breakthrough therapy status for Nuvalents NVL-655 (Pharmaceutical Technology)
May-16-24 04:23PM	Nuvalent Gets Breakthrough Therapy Designation for Lung Cancer Treatment Candidate (MT Newswires)
04:01PM	Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 (PR Newswire)
May-09-24 01:56PM	NUVL Stock Earnings: Nuvalent Misses EPS for Q1 2024 (InvestorPlace)
09:27AM	Nuvalent Q1 Loss Widens (RTT News)
07:19AM	Loading…
07:19AM	Nuvalent Q1 Net Loss Widens (MT Newswires)
06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results (PR Newswire)
May-08-24 05:22PM	Nuvalent Insider Sold Shares Worth $2,605,525, According to a Recent SEC Filing (MT Newswires)
10:21AM	Why Earnings Season Could Be Great for Nuvalent (NUVL) (Zacks)
May-01-24 05:05PM	Nuvalent Insider Sold Shares Worth $2,666,555, According to a Recent SEC Filing (MT Newswires)
Apr-08-24 04:30PM	Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 (PR Newswire)
Apr-05-24 07:00PM	Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-29-24 07:01PM	Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-25-24 07:01PM	Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-19-24 07:01PM	Director Emily Conley Sells 13,333 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-05-24 04:52PM	Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 (PR Newswire)
Feb-29-24 04:32AM	Nuvalent Inc (NUVL) Reports Full Year and Q4 2023 Financial Results with Strong Cash Position ... (GuruFocus.com)
Feb-27-24 06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
06:15AM	Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 (PR Newswire)
Feb-22-24 04:00AM	13 Best Short Squeeze Stocks To Buy Now (Insider Monkey)
Feb-12-24 06:30AM	Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors (PR Newswire)
Feb-01-24 06:30AM	Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (PR Newswire)
Jan-08-24 06:30AM	Nuvalent Announces 'OnTarget 2026' Operating Plan and Key Anticipated Milestones (PR Newswire)
Dec-22-23 03:01PM	Director Anna Protopapas Sells 5,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Dec-21-23 01:01PM	Chief Development Officer Darlene Noci Sells 40,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
06:30AM	Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Nov-14-23 07:15PM	Nuvalent Inc (NUVL) Reports Q3 2023 Financial Results and Pipeline Progress (GuruFocus.com)
06:30AM	Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-04-23 07:02AM	Insider Sell: Darlene Noci Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Nov-01-23 06:30AM	Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day (PR Newswire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-17-23 06:27PM	Why Nuvalent Stock Tanked on Tuesday (Motley Fool) -8.28%
Oct-16-23 09:55PM	Nuvalent Announces Pricing of Public Offering of Common Stock (PR Newswire)
07:30AM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
Oct-13-23 06:30AM	Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC (PR Newswire)
Oct-07-23 01:00AM	Insider Sell: Chief Medical Officer Christopher Turner Sells 7,995 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Oct-05-23 07:13PM	Why Nuvalent Stock Skyrocketed 35% This Week (Motley Fool) +8.52%
10:29AM	Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data (Zacks)
01:01AM	Insider Sell: Darlene Noci Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Oct-04-23 04:13PM	Why Nuvalent Stock Was Soaring Wednesday (Motley Fool) +35.57%
12:21PM	Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile (PR Newswire)
Sep-18-23 06:30AM	Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium (PR Newswire) -6.08%
Sep-05-23 06:30AM	Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors (PR Newswire)
Aug-31-23 06:30AM	Nuvalent to Participate in Upcoming September Investor Conferences (PR Newswire)
Aug-17-23 06:40AM	7 A-Rated Biotech Stocks for Your August Buy List (InvestorPlace)
Aug-10-23 06:30AM	Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results (PR Newswire)
Aug-08-23 10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Aug-01-23 06:30AM	Nuvalent to Participate in Upcoming August Investor Conferences (PR Newswire)
Jul-21-23 08:50AM	Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why (Zacks)
Jun-07-23 08:50AM	Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-24-23 06:30AM	Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit (PR Newswire)
May-11-23 06:30AM	Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results (PR Newswire)
Apr-19-23 06:30AM	Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days (PR Newswire) +5.13%
Apr-18-23 09:00AM	Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023 (PR Newswire)
Apr-02-23 10:56AM	Nuvalent (NASDAQ:NUVL) Is In A Strong Position To Grow Its Business (Simply Wall St.)
Mar-23-23 06:30AM	Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023) (PR Newswire)
Mar-16-23 06:30AM	Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results (PR Newswire) +5.45%
Mar-14-23 05:59PM	Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023 (PR Newswire) +6.05% -6.24%
Mar-01-23 06:30AM	Nuvalent to Participate in the 43rd Annual Cowen Healthcare Conference (PR Newswire)
Jan-04-23 06:30AM	Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-02-23 09:40AM	Are Medical Stocks Lagging DICE Therapeutics (DICE) This Year? (Zacks)
Dec-13-22 10:15AM	Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520 (PR Newswire)
Dec-12-22 03:44PM	12 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Dec-02-22 08:50AM	Here's Why Momentum in Nuvalent, Inc. (NUVL) Should Keep going (Zacks)
Nov-17-22 12:00PM	What Makes Nuvalent, Inc. (NUVL) a Strong Momentum Stock: Buy Now? (Zacks)
Nov-10-22 06:30AM	Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results (PR Newswire)
Nov-03-22 08:13PM	Nuvalent Announces Closing of Upsized Public Offering of Common Stock (PR Newswire) -6.04% +5.13%
Oct-31-22 09:14PM	Nuvalent Announces Pricing of Public Offering of Common Stock (PR Newswire) -5.63%
07:15AM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
Oct-28-22 04:18PM	Nuvalent stock jumps on positive data from cancer drug trial (American City Business Journals) +60.64%
04:06PM	Recent IPO Stock Nuvalent Is Flirting With A Record High On A Tricky Cancer Win (Investor's Business Daily)
11:10AM	Why Nuvalent Shares Are Surging 45% Today? (Benzinga)
12:01AM	Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC (PR Newswire)
Oct-26-22 06:30AM	Nuvalent Announces New Preclinical Data for Selective Kinase Inhibitors NVL-330 and NVL-655 (PR Newswire)

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Porter James Richard	President and CEO	Jan 15 '25	Option Exercise	27.85	27,000	751,950	276,062	Jan 17 04:43 PM
Porter James Richard	President and CEO	Jan 15 '25	Sale	75.99	27,000	2,051,777	249,062	Jan 17 04:43 PM
James Richard Porter	Officer	Jan 15 '25	Proposed Sale	72.39	81,000	5,863,590		Jan 15 05:10 PM
Pelish Henry E.	Chief Scientific Officer	Jan 06 '25	Sale	79.68	2,483	197,854	59,981	Jan 08 05:05 PM
Noci Darlene	Chief Development Officer	Jan 06 '25	Sale	79.68	4,016	320,009	48,034	Jan 08 04:56 PM
Miller Deborah Ann	Chief Legal Officer	Jan 06 '25	Sale	79.68	2,964	236,182	49,086	Jan 08 04:53 PM
Turner Christopher Durant	Chief Medical Officer	Jan 06 '25	Sale	79.68	4,016	320,009	62,547	Jan 08 04:50 PM
Balcom Alexandra	Chief Financial Officer	Jan 06 '25	Sale	79.68	4,016	320,009	61,734	Jan 08 04:48 PM
Porter James Richard	President and CEO	Jan 06 '25	Sale	79.68	17,301	1,378,604	249,062	Jan 08 04:45 PM
Darlene Noci	Officer	Jan 06 '25	Proposed Sale	80.78	4,250	343,315		Jan 06 06:01 AM
Christopher Durant Turner	Officer	Jan 06 '25	Proposed Sale	80.78	4,250	343,315		Jan 06 06:01 AM
Alexandra Balcom	Officer	Jan 06 '25	Proposed Sale	80.78	4,250	343,315		Jan 06 06:01 AM
Deborah Ann Miller	Officer	Jan 06 '25	Proposed Sale	80.78	3,250	262,535		Jan 06 06:01 AM
Henry E. Pelish	Officer	Jan 06 '25	Proposed Sale	80.78	2,750	222,145		Jan 06 06:01 AM
James Richard Porter	Officer	Jan 06 '25	Proposed Sale	80.78	18,000	1,454,040		Jan 06 06:01 AM
Shair Matthew	Director	Dec 23 '24	Sale	83.78	2,000	167,565	220,522	Dec 26 04:49 PM
Porter James Richard	President and CEO	Dec 19 '24	Option Exercise	0.65	22,000	14,300	210,113	Dec 20 04:46 PM
Balcom Alexandra	Chief Financial Officer	Dec 17 '24	Option Exercise	4.88	13,700	66,923	47,000	Dec 18 04:53 PM
Pelish Henry E.	Chief Scientific Officer	Dec 16 '24	Option Exercise	0.75	10,414	7,759	43,714	Dec 18 04:50 PM
Porter James Richard	President and CEO	Dec 16 '24	Option Exercise	27.85	27,000	751,950	215,113	Dec 18 04:49 PM
Porter James Richard	President and CEO	Dec 16 '24	Sale	86.61	27,000	2,338,436	188,113	Dec 18 04:49 PM
Hack Andrew A. F.	Director	Dec 11 '24	Sale	88.00	1,250,000	110,000,000	1,447,267	Dec 13 04:30 PM
BCIP Life Sciences Associates,	Affiliate	Dec 11 '24	Proposed Sale	93.61	135,714	12,704,188		Dec 11 09:14 PM
Bain Capital Life Sciences Fun	Affiliate	Dec 11 '24	Proposed Sale	93.61	1,114,286	104,308,312		Dec 11 09:13 PM
Balcom Alexandra	Chief Financial Officer	Nov 29 '24	Option Exercise	27.85	10,000	278,500	43,300	Dec 03 04:46 PM
Balcom Alexandra	Chief Financial Officer	Nov 29 '24	Sale	95.79	10,000	957,940	33,300	Dec 03 04:46 PM
Shair Matthew	Director	Nov 25 '24	Sale	96.22	2,000	192,443	222,522	Nov 27 04:48 PM
Matthew Shair	Director	Nov 25 '24	Proposed Sale	96.45	8,000	771,600		Nov 25 04:12 PM
Porter James Richard	President and CEO	Nov 15 '24	Option Exercise	27.85	27,000	751,950	215,113	Nov 19 04:45 PM
Porter James Richard	President and CEO	Nov 15 '24	Sale	87.94	27,000	2,374,479	188,113	Nov 19 04:45 PM
Noci Darlene	Chief Development Officer	Nov 01 '24	Option Exercise	14.40	5,000	72,000	38,300	Nov 04 04:49 PM
Noci Darlene	Chief Development Officer	Nov 01 '24	Sale	88.60	5,000	442,980	33,300	Nov 04 04:49 PM
Balcom Alexandra	Chief Financial Officer	Oct 31 '24	Option Exercise	27.85	10,000	278,500	43,300	Nov 04 04:46 PM
Balcom Alexandra	Chief Financial Officer	Oct 31 '24	Sale	89.19	10,000	891,879	33,300	Nov 04 04:46 PM
Shair Matthew	Director	Oct 28 '24	Sale	91.73	2,000	183,468	224,522	Oct 30 04:46 PM
Flynn James E	Director	Oct 22 '24	Sale	97.75	2,000,000	195,500,000	8,670,512	Oct 24 04:08 PM
Deerfield Healthcare Innovatio	Stockholder	Oct 22 '24	Proposed Sale	101.16	1,000,000	101,160,000		Oct 22 04:46 PM
Deerfield Private Design Fund	Stockholder	Oct 22 '24	Proposed Sale	101.16	1,000,000	101,160,000		Oct 22 04:44 PM
Porter James Richard	President and CEO	Oct 15 '24	Option Exercise	27.85	27,000	751,950	215,113	Oct 17 04:45 PM
Porter James Richard	President and CEO	Oct 15 '24	Sale	102.28	27,000	2,761,631	188,113	Oct 17 04:45 PM
James Richard Porter	Officer	Oct 15 '24	Proposed Sale	102.38	81,000	8,292,780		Oct 15 04:23 PM
Noci Darlene	Chief Development Officer	Oct 01 '24	Option Exercise	18.93	5,000	94,650	38,300	Oct 02 05:34 PM
Noci Darlene	Chief Development Officer	Oct 01 '24	Sale	101.74	5,000	508,718	33,300	Oct 02 05:34 PM
Balcom Alexandra	Chief Financial Officer	Sep 30 '24	Option Exercise	27.85	10,000	278,500	43,300	Oct 02 05:33 PM
Balcom Alexandra	Chief Financial Officer	Sep 30 '24	Sale	101.06	10,000	1,010,620	33,300	Oct 02 05:33 PM
Darlene Noci	Officer	Oct 01 '24	Proposed Sale	101.19	10,000	1,011,900		Oct 01 04:16 PM
Alexandra Balcom	Officer	Sep 30 '24	Proposed Sale	102.12	30,000	3,063,600		Sep 30 04:12 PM
Shair Matthew	Director	Sep 23 '24	Sale	102.75	2,000	205,500	226,522	Sep 25 04:44 PM
Pelish Henry E.	Chief Scientific Officer	Sep 16 '24	Sale	98.92	32,795	3,244,140	33,300	Sep 18 04:53 PM
Miller Deborah Ann	Chief Legal Officer	Sep 16 '24	Option Exercise	18.93	8,000	151,440	41,300	Sep 18 04:50 PM
Miller Deborah Ann	Chief Legal Officer	Sep 16 '24	Sale	96.47	8,000	771,798	33,300	Sep 18 04:50 PM
Miller Deborah Ann	Chief Legal Officer	Sep 09 '24	Option Exercise	6.89	3,000	20,670	36,300	Sep 11 04:55 PM
Miller Deborah Ann	Chief Legal Officer	Sep 09 '24	Sale	88.18	3,000	264,546	33,300	Sep 11 04:55 PM
Noci Darlene	Chief Development Officer	Sep 03 '24	Option Exercise	18.93	5,000	94,650	38,300	Sep 04 07:52 PM
Noci Darlene	Chief Development Officer	Sep 03 '24	Sale	84.43	5,000	422,146	33,300	Sep 04 07:52 PM
Balcom Alexandra	Chief Financial Officer	Aug 30 '24	Option Exercise	27.85	10,000	278,500	43,300	Sep 04 04:52 PM
Balcom Alexandra	Chief Financial Officer	Aug 30 '24	Sale	84.23	10,000	842,349	33,300	Sep 04 04:52 PM
Shair Matthew	Director	Aug 26 '24	Sale	84.46	2,000	168,914	228,522	Aug 27 04:51 PM
Pelish Henry E.	Chief Scientific Officer	Aug 23 '24	Sale	85.08	10,500	893,340	66,095	Aug 27 04:49 PM
Miller Deborah Ann	Chief Legal Officer	Aug 23 '24	Option Exercise	23.80	11,000	261,750	44,300	Aug 27 04:47 PM
Miller Deborah Ann	Chief Legal Officer	Aug 23 '24	Sale	85.04	11,000	935,440	33,300	Aug 27 04:47 PM
Conley Emily	Director	Aug 23 '24	Option Exercise	13.79	3,334	45,976	5,841	Aug 27 04:44 PM
Conley Emily	Director	Aug 23 '24	Sale	85.02	3,334	283,457	2,507	Aug 27 04:44 PM
Henry Pelish	Chief Scientific Officer	Aug 23 '24	Proposed Sale	84.13	43,295	3,642,408		Aug 23 04:07 PM
Miller Deborah Ann	Chief Legal Officer	Aug 08 '24	Option Exercise	6.89	3,000	20,670	36,300	Aug 09 04:48 PM
Miller Deborah Ann	Chief Legal Officer	Aug 08 '24	Sale	68.78	3,000	206,348	33,300	Aug 09 04:48 PM
Noci Darlene	Chief Development Officer	Aug 01 '24	Option Exercise	18.93	5,000	94,650	38,300	Aug 02 04:45 PM
Noci Darlene	Chief Development Officer	Aug 01 '24	Sale	77.22	5,000	386,125	33,300	Aug 02 04:45 PM
Balcom Alexandra	Chief Financial Officer	Jul 31 '24	Option Exercise	27.85	10,000	278,500	43,300	Aug 02 04:43 PM
Balcom Alexandra	Chief Financial Officer	Jul 31 '24	Sale	79.51	10,000	795,074	33,300	Aug 02 04:43 PM
Shair Matthew	Director	Jul 29 '24	Sale	79.59	2,000	159,176	230,522	Jul 31 04:46 PM
Matthew Shair	Director	Jul 29 '24	Proposed Sale	81.68	8,000	653,440		Jul 29 04:09 PM
Conley Emily	Director	Jul 15 '24	Option Exercise	13.79	5,000	68,950	7,507	Jul 16 04:47 PM
Conley Emily	Director	Jul 15 '24	Sale	80.72	5,000	403,621	2,507	Jul 16 04:47 PM
Miller Deborah Ann	Chief Legal Officer	Jul 12 '24	Option Exercise	27.85	6,000	167,100	39,300	Jul 16 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Jul 12 '24	Sale	80.16	6,000	480,960	33,300	Jul 16 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Jul 08 '24	Option Exercise	6.89	3,000	20,670	36,300	Jul 10 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Jul 08 '24	Sale	73.23	3,000	219,687	33,300	Jul 10 04:45 PM
Noci Darlene	Chief Development Officer	Jul 01 '24	Option Exercise	18.93	5,000	94,650	38,300	Jul 02 04:47 PM
Noci Darlene	Chief Development Officer	Jul 01 '24	Sale	75.54	5,000	377,696	33,300	Jul 02 04:47 PM
Balcom Alexandra	Chief Financial Officer	Jun 28 '24	Option Exercise	27.85	10,000	278,500	43,300	Jul 02 04:44 PM
Balcom Alexandra	Chief Financial Officer	Jun 28 '24	Sale	75.43	10,000	754,341	33,300	Jul 02 04:44 PM
Shair Matthew	Director	Jun 24 '24	Sale	80.22	2,000	160,438	232,522	Jun 26 04:54 PM
Conley Emily	Director	Jun 14 '24	Option Exercise	13.79	5,000	68,950	7,507	Jun 18 04:15 PM
Conley Emily	Director	Jun 14 '24	Sale	77.56	5,000	387,776	2,507	Jun 18 04:15 PM
Miller Deborah Ann	Chief Legal Officer	Jun 06 '24	Option Exercise	14.41	8,000	115,320	41,300	Jun 07 04:44 PM
Miller Deborah Ann	Chief Legal Officer	Jun 06 '24	Sale	80.40	8,000	643,213	33,300	Jun 07 04:44 PM
Shair Matthew	Director	May 28 '24	Sale	67.22	2,000	134,438	234,522	May 29 04:43 PM
Conley Emily	Director	May 15 '24	Option Exercise	12.31	5,000	61,565	5,008	May 17 04:41 PM
Conley Emily	Director	May 15 '24	Sale	69.09	5,000	345,450	8	May 17 04:41 PM
Shair Matthew	Director	May 13 '24	Sale	65.84	37,500	2,468,866	1,424,698	May 15 04:54 PM
Shair Matthew	Director	May 06 '24	Sale	69.48	37,500	2,605,525	1,462,198	May 08 04:51 PM
Miller Deborah Ann	Chief Legal Officer	May 02 '24	Option Exercise	6.89	3,000	20,670	36,300	May 03 04:47 PM
Miller Deborah Ann	Chief Legal Officer	May 02 '24	Sale	72.07	3,000	216,203	33,300	May 03 04:47 PM
Shair Matthew	Director	Apr 29 '24	Sale	67.51	37,500	2,531,537	1,499,698	May 01 04:41 PM
Shair Matthew	Director	Apr 29 '24	Sale	67.51	2,000	135,018	236,522	May 01 04:41 PM
Shair Matthew	Director	Apr 22 '24	Sale	63.65	37,500	2,386,910	1,537,198	Apr 24 04:44 PM
Shair Matthew	Director	Apr 15 '24	Sale	65.56	37,500	2,458,335	1,574,698	Apr 17 04:46 PM
Conley Emily	Director	Apr 15 '24	Option Exercise	9.36	5,000	46,800	5,008	Apr 17 04:44 PM
Conley Emily	Director	Apr 15 '24	Sale	65.52	5,000	327,607	8	Apr 17 04:44 PM

Open in Screener

BCAX

Bicara Therapeutics Inc

Jan 17 • 04:00PM ET

12.11

Dollar change +0.23
Percentage change 1.94	%

Healthcare • Biotechnology • USA • NASD

BCAX Bicara Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF VTWO IWO SCHA FESM IWN VTWG ONEQ

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	40.20%	Shs Outstand	54.41M	Perf Week	-15.79%
Market Cap	658.97M	Forward P/E	-	EPS next Y	-	Insider Trans	9.53%	Shs Float	32.54M	Perf Month	-30.44%
Income	-	PEG	-	EPS next Q	-0.34	Inst Own	45.40%	Short Float	13.89%	Perf Quarter	-40.05%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	39.69%	Short Ratio	10.75	Perf Half Y	-
Book/sh	9.37	P/B	1.29	EPS next Y	-	ROA	-	Short Interest	4.52M	Perf Year	-
Cash/sh	9.57	P/C	1.27	EPS next 5Y	-	ROE	-	52W Range	11.56 - 28.09	Perf YTD	-30.48%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-56.89%	Beta	-
Dividend TTM	-	Quick Ratio	36.01	Sales past 5Y	0.00%	Gross Margin	-	52W Low	4.78%	ATR (14)	1.46
Dividend Ex-Date	-	Current Ratio	36.01	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	26.40	Volatility	11.29% 8.96%
Employees	-	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	43.25
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-	Payout	-	Rel Volume	0.56	Prev Close	11.88
Sales Surprise	-	EPS Surprise	-290.24%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	420.65K	Price	12.11
SMA20	-23.72%	SMA50	-34.84%	SMA200	-41.31%	Trades		Volume	234,931	Change	1.94%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-24	Initiated	H.C. Wainwright	Buy	$42
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$48
Oct-08-24	Initiated	TD Cowen	Buy
Oct-08-24	Initiated	Stifel	Buy	$47
Oct-08-24	Initiated	Morgan Stanley	Overweight	$35
Oct-08-24	Initiated	Cantor Fitzgerald	Overweight

Jan-08-25 10:16AM	Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia (Clinical Trials Arena)
Nov-12-24 07:30AM	Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -7.30%
Nov-11-24 04:01PM	Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Oct-08-24 10:44AM	MBX Biosciences earns Buy rating at three investment firms (Investing.com) -7.77%
07:05PM	Loading…
Sep-23-24 07:05PM	RA Capital Management's Strategic Acquisition of Bicara Therapeutics Shares (GuruFocus.com)
Sep-19-24 01:13AM	TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc (GuruFocus.com)
Sep-18-24 03:01PM	FMR LLC Acquires New Stake in Bicara Therapeutics Inc (GuruFocus.com)
Sep-17-24 09:13AM	Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity (Pharmaceutical Technology) +6.53%
Sep-16-24 04:01PM	Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +8.54%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 09:15PM	Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
07:02PM	Three biotechs raise $700M in rare burst of IPO activity (BioPharma Dive)

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and it developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company's bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, is a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	Sep 16 '24	Buy	18.00	1,833,000	32,994,000	4,303,418	Sep 18 06:02 PM
Flynn James E	Possible Members of 10% Group	Sep 17 '24	Buy	18.00	70,000	1,260,000	897,587	Sep 17 06:16 PM

Open in Screener

AHCO

AdaptHealth Corp

Jan 17 • 04:00PM ET

10.52

Dollar change +0.14
Percentage change 1.35	%

Healthcare • Medical Devices • USA • NASD

Peers: DVA OPCH AMED EHC PNTG CHE MD RDNT ADUS MODV

| Held by: CALF IJR IWM VTI VB VXF IJS SPSM VBR BSVO

Index	RUT	P/E	-	EPS (ttm)	-1.65	Insider Own	35.35%	Shs Outstand	131.60M	Perf Week	3.75%
Market Cap	1.42B	Forward P/E	10.55	EPS next Y	1.00	Insider Trans	-0.44%	Shs Float	86.99M	Perf Month	5.20%
Income	-217.93M	PEG	-	EPS next Q	0.28	Inst Own	68.57%	Short Float	9.78%	Perf Quarter	-3.13%
Sales	3.26B	P/S	0.43	EPS this Y	-30.16%	Inst Trans	18.15%	Short Ratio	7.34	Perf Half Y	-1.87%
Book/sh	11.52	P/B	0.91	EPS next Y	8.42%	ROA	-4.74%	Short Interest	8.51M	Perf Year	58.43%
Cash/sh	0.74	P/C	14.13	EPS next 5Y	7.26%	ROE	-13.42%	52W Range	6.46 - 11.90	Perf YTD	10.50%
Dividend Est.	-	P/FCF	6.17	EPS past 5Y	-	ROI	-5.99%	52W High	-11.60%	Beta	1.11
Dividend TTM	-	Quick Ratio	1.00	Sales past 5Y	65.14%	Gross Margin	14.78%	52W Low	62.85%	ATR (14)	0.44
Dividend Ex-Date	-	Current Ratio	1.24	EPS Y/Y TTM	48.49%	Oper. Margin	8.88%	RSI (14)	62.08	Volatility	4.22% 4.63%
Employees	10700	Debt/Eq	1.44	Sales Y/Y TTM	4.49%	Profit Margin	-6.68%	Recom	1.78	Target Price	11.39
Option/Short	Yes / Yes	LT Debt/Eq	1.40	EPS Q/Q	104.55%	Payout	-	Rel Volume	0.52	Prev Close	10.38
Sales Surprise	-0.43%	EPS Surprise	17.20%	Sales Q/Q	0.23%	Earnings	Nov 05 BMO	Avg Volume	1.16M	Price	10.52
SMA20	5.65%	SMA50	6.25%	SMA200	2.28%	Trades		Volume	599,683	Change	1.35%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-24	Downgrade	Jefferies	Buy → Hold	$14.50 → $8
Nov-08-23	Downgrade	BofA Securities	Neutral → Underperform	$9.50 → $6.50
May-10-23	Downgrade	Stifel	Buy → Hold	$18 → $11
May-10-23	Downgrade	Deutsche Bank	Buy → Hold	$28 → $11.30
May-09-23	Downgrade	BofA Securities	Buy → Neutral	$21 → $12
Sep-27-21	Initiated	SVB Leerink	Outperform	$30
Jul-14-21	Upgrade	Robert W. Baird	Neutral → Outperform	$30 → $36
Apr-13-21	Downgrade	Robert W. Baird	Outperform → Neutral
Mar-18-21	Initiated	Truist	Buy
Jan-26-21	Initiated	BofA Securities	Buy	$46
Dec-10-20	Initiated	UBS	Buy	$49
Aug-10-20	Initiated	Canaccord Genuity	Buy	$31
Jul-01-20	Resumed	SVB Leerink	Outperform	$21
Jun-09-20	Initiated	RBC Capital Mkts	Outperform	$24
Jan-31-20	Initiated	Stifel	Buy	$17
Jan-07-20	Initiated	Jefferies	Buy	$15
Dec-11-19	Initiated	SVB Leerink	Outperform
Dec-10-19	Initiated	Deutsche Bank	Buy

Show Previous Ratings

Dec-03-24 08:00AM	AdaptHealth Corp. Announces Appointment of Russell Schuster as Chief Commercial Officer (Business Wire)
Nov-26-24 04:05PM	AdaptHealth Corp. to Participate in the BofA Securities Home Care Conference 2024 (Business Wire)
08:34AM	Implied Volatility Surging for AdaptHealth (AHCO) Stock Options (Zacks)
Nov-12-24 04:05PM	AdaptHealth Corp. to Participate in the Stifel 2024 Healthcare Conference (Business Wire)
Nov-06-24 02:11AM	AdaptHealth Corp (AHCO) Q3 2024 Earnings Call Highlights: Navigating Growth and Challenges (GuruFocus.com) +10.89%
06:42PM	Loading…
Nov-05-24 06:42PM	Why AdaptHealth Stock Got Thrashed on Tuesday (Motley Fool) -9.56%
08:40AM	AdaptHealth Corp. (AHCO) Surpasses Q3 Earnings Estimates (Zacks)
07:26AM	AdaptHealth Corp. Announces Third Quarter 2024 Results (Business Wire)
Oct-24-24 09:40AM	Are Investors Undervaluing AdaptHealth (AHCO) Right Now? (Zacks)
09:40AM	Are Medical Stocks Lagging AdaptHealth (AHCO) This Year? (Zacks)
Oct-22-24 10:01AM	Do Options Traders Know Something About AdaptHealth (AHCO) Stock We Don't? (Zacks)
Oct-17-24 08:00AM	AdaptHealth Appoints Diana Nole to Board of Directors (Business Wire)
Oct-16-24 08:30AM	AdaptHealth Corp. Announces Third Quarter 2024 Earnings Release Date and Conference Call (Business Wire)
Oct-09-24 05:02PM	AdaptHealth Corp (AHCO) Q2 2024 Earnings Call Highlights: Strategic Growth Amidst Revenue Shifts (GuruFocus.com)
Oct-08-24 09:40AM	Is AdaptHealth (AHCO) Stock Undervalued Right Now? (Zacks)
03:28PM	Loading…
Sep-17-24 03:28PM	AdaptHealth Stock Earns RS Rating Upgrade (Investor's Business Daily)
Sep-16-24 08:00AM	AdaptHealth Corp. Announces Refinancing of Senior Secured Credit Facility Resulting in Extended Maturity and Reduced Cost of Debt (Business Wire)
Aug-27-24 08:30AM	AdaptHealth Corp. to Participate in the Baird 2024 Global Healthcare Conference (Business Wire)
Aug-26-24 07:30AM	AdaptHealth Corp. Announces New Chief Operating Officer (Business Wire)
Aug-08-24 04:05PM	AdaptHealth Corp. to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire)
Aug-06-24 08:30AM	AdaptHealth Corp. (AHCO) Beats Q2 Earnings and Revenue Estimates (Zacks) -21.06%
07:00AM	AdaptHealth Corp. Announces Second Quarter 2024 Results (Business Wire)
Jul-16-24 08:30AM	AdaptHealth Corp. Announces Second Quarter 2024 Earnings Release Date and Conference Call (Business Wire) +5.31%
Jul-12-24 09:13AM	Implied Volatility Surging for AdaptHealth (AHCO) Stock Options (Zacks)
Jul-02-24 05:21PM	AdaptHealth Corp. Announces Changes to Board of Directors and Management (Business Wire)
May-22-24 04:39PM	AdaptHealth Corp. to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
04:36PM	AdaptHealth Corp. to Participate in the Jefferies Global Healthcare Conference (Business Wire)
04:33PM	AdaptHealth Corp. to Participate in the UBS Healthcare Services Cape Cod Summit (Business Wire)
04:30PM	AdaptHealth Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-20-24 04:05PM	AdaptHealth Corp. to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference (Business Wire)
04:45PM	Loading…
May-14-24 04:45PM	3 High-Potential Stocks to Buy at Rock-Bottom Prices (InvestorPlace)
May-08-24 02:57PM	AdaptHealth Corp. (NASDAQ:AHCO) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:00AM	AdaptHealth Corp. to Participate in the BofA Securities 2024 Health Care Conference (Business Wire)
03:19AM	AdaptHealth Corp (AHCO) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue and EBITDA ... (GuruFocus.com)
May-07-24 09:48AM	AdaptHealth's Shares Fall After Q1 Net Loss Misses Analysts' Forecast (MT Newswires) -7.92%
08:43AM	Owlet, Inc. (NYSE:OWLT) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:36AM	AdaptHealth Corp Reports Mixed Q1 2024 Results: Revenue Up, Net Loss Recorded (GuruFocus.com)
08:10AM	AdaptHealth Corp. (AHCO) Lags Q1 Earnings Estimates (Zacks)
07:00AM	AdaptHealth Corp. Announces First Quarter 2024 Results (Business Wire)
Apr-24-24 09:40AM	Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Apr-18-24 08:00AM	AdaptHealth Corp. Announces First Quarter 2024 Earnings Release Date and Conference Call (Business Wire)
Apr-17-24 06:51PM	Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank (Motley Fool)
04:15PM	AdaptHealth Appoints Suzanne Foster as Chief Executive Officer (Business Wire)
Apr-08-24 09:40AM	Are Medical Stocks Lagging AdaptHealth (AHCO) This Year? (Zacks)
Mar-22-24 09:40AM	Are Medical Stocks Lagging AdaptHealth (AHCO) This Year? (Zacks)
Mar-08-24 11:59AM	Owlet, Inc. (NYSE:OWLT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 09:40AM	Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-04-24 04:05PM	AdaptHealth Corp. to Participate in the Barclays 26th Annual Global Healthcare Conference (Business Wire)
Mar-01-24 08:00AM	AdaptHealth Corp. to Participate in the 3rd Annual Jefferies Value Based Care Summit (Business Wire)
Feb-28-24 10:53AM	AdaptHealth Corp. (NASDAQ:AHCO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 10:53PM	Q4 2023 Adapthealth Corp Earnings Call (Thomson Reuters StreetEvents) +31.06%
11:28AM	Why AdaptHealth Stock Is Skyrocketing Today (Motley Fool)
07:33AM	AdaptHealth Corp (AHCO) Reports Solid Revenue Growth Amidst Net Loss Due to Goodwill Write-Down (GuruFocus.com)
07:00AM	AdaptHealth Corp. Announces Fourth Quarter and Full-Year 2023 Results and Provides Initial 2024 Outlook (Business Wire)
Feb-08-24 04:05PM	AdaptHealth Corp. Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Conference Call (Business Wire)
Dec-19-23 05:05PM	AdaptHealth Corp. to Participate in Upcoming Investor Conference (Business Wire) -17.32%
Nov-10-23 08:00AM	AdaptHealth Corp. to Participate in Upcoming Investor Conferences (Business Wire)
Nov-08-23 05:11PM	AdaptHealth Corp. (NASDAQ:AHCO) Q3 2023 Earnings Call Transcript (Insider Monkey) -15.47%
Nov-07-23 11:41PM	Q3 2023 Adapthealth Corp Earnings Call (Thomson Reuters StreetEvents) -8.99%
08:11AM	AdaptHealth Corp (AHCO) Reports 6.3% Increase in Q3 Net Revenue Despite Net Loss (GuruFocus.com)
07:00AM	AdaptHealth Corp. Announces Third Quarter 2023 Results (Business Wire)
Oct-17-23 04:05PM	AdaptHealth Corp. Announces Third Quarter 2023 Earnings Release Date and Conference Call (Business Wire)
Oct-11-23 12:07PM	AdaptHealth Corp (AHCO): A Deep Dive into Its Performance Metrics (GuruFocus.com) -10.40%
Sep-20-23 12:47PM	Coty, Steelcase rise; Eastern Bankshares, AdaptHealth fall, Wednesday, 9/20/2023 (Associated Press Finance) -6.49%
11:44AM	Is AdaptHealth (AHCO) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com)
08:54AM	UPDATE 3-AdaptHealth says terminated appointment contract for incoming CEO (Reuters)
08:45AM	AdaptHealth says terminated appointment contract for incoming CEO (Reuters)
08:38AM	Do Options Traders Know Something About AdaptHealth (AHCO) Stock We Don't? (Zacks)
Sep-14-23 07:37PM	Is AdaptHealth (AHCO) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com)
01:31PM	AdaptHealth Corp (AHCO): A Deep Dive into Its Performance Potential (GuruFocus.com)
Sep-07-23 08:00AM	AdaptHealth Corp. to Participate in Bairds 2023 Global Healthcare Conference (Business Wire)
Aug-17-23 07:17PM	Why AdaptHealth Stock Dropped Today (Motley Fool) -13.81%
07:31AM	AdaptHealth says incoming CEO sued by former employer Linde (Reuters)
Aug-08-23 10:50AM	AdaptHealth Corp. (AHCO) Q2 Earnings and Revenues Top Estimates (Zacks) +10.38%
06:30AM	AdaptHealth Corp. Announces Second Quarter 2023 Results (Business Wire)
Aug-03-23 08:00AM	AdaptHealth Corp. to Participate in the Canaccord Genuity 43rd Annual Growth Conference (Business Wire)
Aug-02-23 01:24PM	Should AdaptHealth Corp. (NASDAQ:AHCO) Focus On Improving This Fundamental Metric? (Simply Wall St.)
Jul-18-23 08:00AM	AdaptHealth Corp. Announces Second Quarter 2023 Earnings Release Date and Conference Call (Business Wire) +7.20%
Jul-17-23 07:27AM	Is It Too Late To Consider Buying AdaptHealth Corp. (NASDAQ:AHCO)? (Simply Wall St.)
Jun-28-23 08:12AM	AdaptHealth Corp. (AHCO) Soars 19.6%: Is Further Upside Left in the Stock? (Zacks)
Jun-27-23 08:16AM	AdaptHealth Appoints Crispin Teufel as New Chief Executive Officer (Business Wire) +19.62%
Jun-21-23 08:00PM	AHCO: What does Argus have to say about AHCO? (Argus Research)
Jun-20-23 08:40AM	Are Options Traders Betting on a Big Move in AdaptHealth (AHCO) Stock? (Zacks)
May-19-23 08:32AM	Implied Volatility Surging for AdaptHealth (AHCO) Stock Options (Zacks)
May-15-23 12:28PM	AdaptHealth to Participate in RBC Global Healthcare Conference (Business Wire)
May-11-23 02:00PM	AdaptHealth Corp. Partners With Humana on Value-Based Care (Business Wire) -8.77%
May-09-23 06:18PM	Why AdaptHealth Stock Got Slammed Today (Motley Fool) -6.38%
08:55AM	AdaptHealth Corp. (AHCO) Q1 Earnings and Revenues Lag Estimates (Zacks)
07:35AM	AdaptHealth Corp. Announces First Quarter 2023 Results (Business Wire)
07:35AM	AdaptHealth Announces Stephen Griggs Will Step Down as CEO at the End of Second Quarter (Business Wire)
Apr-26-23 08:00PM	AHCO: What does Argus have to say about AHCO? (Argus Research)
Apr-18-23 08:32AM	Implied Volatility Surging for AdaptHealth (AHCO) Stock Options (Zacks)
Apr-17-23 09:10AM	There Are Reasons To Feel Uneasy About AdaptHealth's (NASDAQ:AHCO) Returns On Capital (Simply Wall St.)
Apr-11-23 04:15PM	AdaptHealth Corp. Announces First Quarter 2023 Earnings Release Date and Conference Call (Business Wire)
Mar-27-23 08:22AM	Investors in AdaptHealth (NASDAQ:AHCO) have unfortunately lost 16% over the last year (Simply Wall St.)
Mar-02-23 05:44AM	AdaptHealth Corp. (NASDAQ:AHCO) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-01-23 05:08AM	Is AdaptHealth Corp. (NASDAQ:AHCO) Trading At A 49% Discount? (Simply Wall St.) -5.38%
01:01AM	Q4 2022 Adapthealth Corp Earnings Call (Thomson Reuters StreetEvents)
Feb-28-23 12:00PM	Why AdaptHealth Stock Is Crashing Today (Motley Fool) -27.25%
10:55AM	AdaptHealth's Q4 Core Earnings Fall Short Of Expectations, Trims Annual Guidance (Benzinga)

AdaptHealth Corp. engages in the provision of home healthcare equipment, supplies and related services. It focuses on sleep therapy equipment to individuals suffering from obstructive sleep apnea (OSA), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and HME medical devices and supplies on behalf of chronically ill patients with diabetes care, wound care, urological, ostomy, and nutritional supply needs. The company was founded in 2012 and is headquartered in Plymouth Meeting, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rietkerk Shaw	Officer	Dec 19 '24	Proposed Sale	9.70	32,500	315,250		Dec 19 11:02 AM
Clemens Jason A	Chief Financial Officer	Dec 10 '24	Sale	9.35	35,000	327,250	420,719	Dec 12 04:35 PM
JASON A CLEMENS &BIANCA S VITA	Officer	Dec 10 '24	Proposed Sale	9.35	35,000	327,408		Dec 10 04:19 PM
Rietkerk Shaw	Officer	Nov 22 '24	Proposed Sale	9.80	40,000	392,079		Nov 22 04:16 PM
WOLF DALE B	Director	Nov 13 '24	Sale	10.80	7,000	75,600	74,889	Nov 15 04:15 PM
WOLF DALE B	Director	Nov 13 '24	Proposed Sale	10.78	7,000	75,460		Nov 13 12:32 PM
Rietkerk Shaw	Former Chief Operating Officer	Sep 20 '24	Sale	11.24	25,000	281,000	212,611	Sep 24 06:25 PM
Rietkerk Shaw	Officer	Sep 20 '24	Proposed Sale	11.24	25,000	281,040		Sep 20 01:22 PM
Richard A. Barasch	Former Affiliate	Sep 18 '24	Proposed Sale	11.48	40,022	459,452		Sep 18 07:20 PM
Richard A. Barasch	Former Affiliate	Sep 16 '24	Proposed Sale	11.13	14,970	166,616		Sep 16 06:38 PM
Richard A. Barasch	Former Affiliate	Sep 12 '24	Proposed Sale	11.31	10,000	113,100		Sep 12 04:53 PM
Prast Albert A.	Chief Technology Officer	Mar 04 '24	Option Exercise	2.69	135,443	364,342	316,526	Sep 05 06:45 PM
Prast Albert A.	Chief Technology Officer	Mar 04 '24	Sale	10.41	135,443	1,409,962	181,083	Sep 05 06:45 PM
Richard A. Barasch	Former Affiliate	Sep 05 '24	Proposed Sale	11.28	13,307	150,103		Sep 05 05:03 PM
Williams David Solomon III	Director	Aug 29 '24	Sale	11.26	4,000	45,040	36,899	Sep 03 08:25 PM
Williams David Solomon III	Director	May 23 '24	Sale	9.90	3,100	30,690	26,679	Sep 03 08:25 PM
Williams David Solomon III	Director	May 24 '24	Sale	9.97	1,409	14,048	25,270	Sep 03 08:25 PM
Richard A. Barasch	Former Affiliate	Aug 28 '24	Proposed Sale	10.79	18,034	194,587		Aug 28 04:17 PM
Richard A. Barasch	Former Affiliate	Aug 19 '24	Proposed Sale	10.46	10,235	107,058		Aug 19 07:08 PM
Richard A. Barasch	Former Affiliate	Aug 15 '24	Proposed Sale	10.04	25,614	257,165		Aug 15 05:00 PM
Flynn James E	10% Owner	Mar 11 '24	Sale	11.02	182,607	2,012,557	11,643,769	Mar 12 07:01 PM
Flynn James E	10% Owner	Mar 12 '24	Sale	10.70	114,906	1,229,494	11,528,863	Mar 12 07:01 PM
Flynn James E	10% Owner	Mar 08 '24	Sale	10.93	52,487	573,652	11,826,376	Mar 12 07:01 PM

LRMR Larimar Therapeutics Inc daily Stock Chart

Peers: VRTX BMRN FOLD QURE RPTX ARWR ONCT SRPT CRSP RIGL

| Held by: VTI IWM VXF IWO VTWO IBB IWC ITOT AVSC SBIO

Index	RUT	P/E	-	EPS (ttm)	-1.15	Insider Own	42.00%	Shs Outstand	63.81M	Perf Week	-8.74%
Market Cap	213.11M	Forward P/E	-	EPS next Y	-1.65	Insider Trans	0.00%	Shs Float	37.01M	Perf Month	-30.85%
Income	-64.77M	PEG	-	EPS next Q	-0.32	Inst Own	60.94%	Short Float	13.70%	Perf Quarter	-56.68%
Sales	0.00M	P/S	-	EPS this Y	-44.76%	Inst Trans	-2.67%	Short Ratio	6.23	Perf Half Y	-64.20%
Book/sh	3.11	P/B	1.07	EPS next Y	-35.41%	ROA	-40.11%	Short Interest	5.07M	Perf Year	-20.67%
Cash/sh	3.19	P/C	1.05	EPS next 5Y	-	ROE	-44.50%	52W Range	3.01 - 13.68	Perf YTD	-13.70%
Dividend Est.	-	P/FCF	-	EPS past 5Y	48.33%	ROI	-31.95%	52W High	-75.58%	Beta	0.92
Dividend TTM	-	Quick Ratio	13.10	Sales past 5Y	0.00%	Gross Margin	-	52W Low	10.96%	ATR (14)	0.35
Dividend Ex-Date	-	Current Ratio	13.10	EPS Y/Y TTM	-51.42%	Oper. Margin	-	RSI (14)	29.01	Volatility	7.05% 7.46%
Employees	42	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.09	Target Price	20.40
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	-17.68%	Payout	-	Rel Volume	0.65	Prev Close	3.25
Sales Surprise	-	EPS Surprise	35.95%	Sales Q/Q	-	Earnings	Oct 30 BMO	Avg Volume	814.39K	Price	3.34
SMA20	-12.04%	SMA50	-40.04%	SMA200	-53.76%	Trades		Volume	527,284	Change	2.77%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-24	Initiated	Oppenheimer	Outperform	$26
Oct-03-24	Initiated	Wedbush	Outperform	$22
Oct-02-24	Initiated	H.C. Wainwright	Buy	$15
Sep-04-24	Initiated	Robert W. Baird	Outperform	$16
Apr-03-24	Initiated	Leerink Partners	Outperform	$25
Nov-17-23	Upgrade	Citigroup	Neutral → Buy	$4.50
Oct-19-22	Initiated	Guggenheim	Buy	$12
Feb-15-22	Downgrade	William Blair	Outperform → Mkt Perform
Feb-10-21	Initiated	JMP Securities	Mkt Outperform
Feb-01-21	Initiated	William Blair	Outperform	$29

Dec-17-24 07:20AM	Larimar Therapeutics announces initial data from OLE study of nomlabofusp (TipRanks) -10.56%
Dec-16-24 07:00AM	Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study and Progress Across Nomlabofusp Program for Friedreich's Ataxia (GlobeNewswire) -21.72%
07:00AM	Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreichs Ataxia (GlobeNewswire)
Nov-18-24 07:00AM	Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 (GlobeNewswire) -7.92%
Oct-30-24 07:00AM	Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results (GlobeNewswire) +8.74%
07:00AM	Loading…
Sep-19-24 07:00AM	Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research (GlobeNewswire)
Aug-27-24 08:00AM	Larimar Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-07-24 07:00AM	Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -6.54%
May-30-24 04:05PM	Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia (GlobeNewswire) +12.68%
May-22-24 11:25AM	Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study (Zacks)
May-21-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +8.53%
May-20-24 04:05PM	Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia (GlobeNewswire)
May-09-24 01:55PM	LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:00AM	Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results (GlobeNewswire)
Mar-20-24 01:32PM	Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks (Insider Monkey)
09:53PM	Loading…
Mar-14-24 09:53PM	LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.51%
05:32PM	Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
04:05PM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development (GlobeNewswire)
Mar-11-24 04:05PM	Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia (GlobeNewswire) -15.39%
Mar-06-24 04:05PM	Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-20-24 01:47PM	Hedge Fund and Insider Trading News: Bill Ackman, George Soros, Arkhouse Management, TYR Capital, Borea Asset Management, Larimar Therapeutics, Inc. (LRMR), and More (Insider Monkey) -5.63%
Feb-19-24 01:48PM	Hedge Fund and Insider Trading News: Bill Ackman, David Tepper, Mark Yusko, Elliott Management, Conestoga Capital Advisors, Larimar Therapeutics Inc (LRMR), Agree Realty Corporation (ADC), and More (Insider Monkey)
Feb-16-24 04:20PM	Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.63%
Feb-14-24 06:15AM	Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock (GlobeNewswire) +36.84%
Feb-13-24 04:18PM	Larimar Therapeutics Announces Proposed Underwritten Public Offering (GlobeNewswire) +11.62%
Feb-12-24 07:00AM	Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia (GlobeNewswire)
Nov-14-23 07:00AM	Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results (GlobeNewswire) +7.11%
Nov-01-23 04:05PM	Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference (GlobeNewswire)
Oct-03-23 04:05PM	Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors (GlobeNewswire) -5.83%
Aug-31-23 04:05PM	Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference (GlobeNewswire)
07:00AM	Loading…
Aug-10-23 07:00AM	Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results (GlobeNewswire)
Aug-07-23 09:22AM	Larimar Therapeutics Insiders Placed Bullish Bets Worth US$1.2m (Simply Wall St.) -7.19%
Jul-25-23 09:59AM	These 2 Strong Buy Penny Stocks Could Go Boom, Say Analysts (TipRanks) +7.67%
07:00AM	Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial (GlobeNewswire)
Jul-17-23 04:05PM	Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer (GlobeNewswire)
Jun-21-23 04:05PM	Larimar Therapeutics Set to Join Russell 3000® Index (GlobeNewswire)
May-15-23 07:00AM	Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trials 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreichs Ataxia and First Quarter 2023 Financial Results (GlobeNewswire) -29.05%
Mar-28-23 04:05PM	Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days (GlobeNewswire)
Mar-14-23 07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results (GlobeNewswire)
Feb-07-23 04:05PM	Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer (GlobeNewswire) +6.52% +7.99%
Nov-21-22 04:05PM	Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-10-22 07:00AM	Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results (GlobeNewswire)
Nov-07-22 04:05PM	Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day (GlobeNewswire)
Oct-20-22 08:00AM	Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601 (GlobeNewswire)
Oct-19-22 04:05PM	Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research (GlobeNewswire)
Sep-16-22 01:00PM	Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares (GlobeNewswire) -5.04%
Sep-14-22 07:04AM	Larimar Therapeutics Announces $70 Million Underwritten Offering (GlobeNewswire) +15.56%
07:01AM	Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreichs Ataxia Patients (GlobeNewswire)
Aug-11-22 04:05PM	Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results (GlobeNewswire) +7.07%
Jul-28-22 04:05PM	Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders (GlobeNewswire)
Jun-28-22 08:00AM	Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts (GlobeNewswire)
06:05AM	We're Keeping An Eye On Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Rate (Simply Wall St.)
Jun-02-22 08:00AM	Larimar Therapeutics Announces Upcoming Scientific Conference Presentations (GlobeNewswire)
May-19-22 08:00AM	Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinsons Disease and Movement Disorders Congress (GlobeNewswire)
May-12-22 07:00AM	Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results (GlobeNewswire) -7.91%
Apr-29-22 06:27AM	Despite recent gains, Larimar Therapeutics, Inc. (NASDAQ:LRMR) insiders are still down US$273k after purchasing last year (Simply Wall St.) -5.84%
Apr-13-22 10:40AM	Down 21.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR) (Zacks)
Mar-25-22 07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results (GlobeNewswire)
Feb-16-22 11:57AM	Larimar Therapeutics' stock plunges on FDA decision; could implement cost-cutting measures (American City Business Journals)
Feb-14-22 04:01PM	Larimar Therapeutics Provides Update on CTI-1601 Clinical Program (GlobeNewswire) -52.09%
Jan-19-22 06:53AM	Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Nov-22-21 07:00AM	Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference (GlobeNewswire)
Nov-20-21 08:40AM	In spite of Larimar Therapeutics, Inc.'s recent pullback, insiders still gained about US$85k after buying earlier this year. (Simply Wall St.)
Nov-15-21 07:00AM	Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference (GlobeNewswire)
Nov-12-21 07:00AM	Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results (GlobeNewswire) -8.72%
Sep-16-21 08:00AM	Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event (GlobeNewswire) -7.48%
Sep-02-21 04:01PM	Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference (GlobeNewswire) +5.81%
Aug-22-21 10:12AM	What You Need To Know About Larimar Therapeutics, Inc.'s (NASDAQ:LRMR) Investor Composition (Simply Wall St.)
Aug-19-21 07:00AM	Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress (GlobeNewswire)
Aug-12-21 07:00AM	Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results (GlobeNewswire) +17.79%
Aug-09-21 08:48AM	Why Larimar (LRMR) Might Surprise This Earnings Season (Zacks)
Jul-23-21 12:00PM	Larimar (LRMR) Upgraded to Buy: Here's Why (Zacks)
Jul-08-21 04:01PM	Larimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021 (GlobeNewswire)
Jun-11-21 07:00AM	Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
Jun-05-21 07:55PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (Newsfile)
Jun-02-21 10:56PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (GlobeNewswire)
Jun-01-21 04:55AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (PR Newswire)
May-29-21 10:59PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (Newsfile)
May-25-21 05:41PM	Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing (GlobeNewswire) -10.59% -33.46%
May-21-21 09:18AM	Larimar Therapeutics Announces $95 Million Private Placement Financing (GlobeNewswire) +11.17%
May-20-21 04:31PM	Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreichs Ataxia (GlobeNewswire) +10.17%
May-11-21 07:00AM	Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreichs Ataxia (GlobeNewswire) -36.28%
May-10-21 04:05PM	Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results (GlobeNewswire) -5.34%
Mar-04-21 07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results (GlobeNewswire)
Mar-01-21 03:54AM	Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation (Simply Wall St.)
Feb-18-21 04:01PM	Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference (GlobeNewswire) +6.38%
Dec-16-20 07:23PM	Is LRMR A Good Stock To Buy Now? (Insider Monkey)
Dec-15-20 08:00AM	Larimar Therapeutics Added to NASDAQ Biotechnology Index (GlobeNewswire)
Dec-08-20 07:30AM	Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreichs Ataxia Patients and Provides Program Update (GlobeNewswire)
Nov-13-20 08:00AM	Larimar Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +16.58%
Nov-10-20 08:00AM	Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results (GlobeNewswire) -6.12%
Oct-14-20 10:18PM	Hedge Funds Are Betting On Larimar Therapeutics, Inc. (LRMR) (Insider Monkey)
Oct-13-20 08:00AM	Larimar Therapeutics Announces Formation of Scientific Advisory Board (GlobeNewswire) +22.55%
Sep-21-20 09:58AM	Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (GlobeNewswire) -6.19%
Sep-10-20 08:00AM	Larimar Therapeutics to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference (GlobeNewswire) +7.50%
Sep-01-20 12:47PM	What Is The Ownership Structure Like For Larimar Therapeutics, Inc. (NASDAQ:LRMR)? (Simply Wall St.)
Aug-11-20 07:00AM	Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results (GlobeNewswire) +9.43%
Aug-04-20 08:00AM	Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-28-20 08:00AM	Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreichs Ataxia (GlobeNewswire)
Jul-20-20 04:15PM	Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreichs Ataxia (GlobeNewswire)

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hamilton Thomas Edward	Director	Feb 16 '24	Buy	8.74	57,208	499,998	564,798	May 31 04:56 PM
Flynn James E	Director	Feb 16 '24	Buy	8.74	4,290,617	37,499,993	6,151,406	Feb 16 02:37 PM
THOMAS FRANK E	Director	Feb 14 '24	Buy	11.00	2,000	22,000	2,000	Feb 15 04:21 PM

SPRY

ARS Pharmaceuticals Inc

NUVL

Nuvalent Inc

BCAX

Bicara Therapeutics Inc

AHCO

AdaptHealth Corp

LRMR

Larimar Therapeutics Inc

Upgrade your FINVIZ experience